558 related articles for article (PubMed ID: 31046833)
1. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.
Noronha NC; Mizukami A; Caliári-Oliveira C; Cominal JG; Rocha JLM; Covas DT; Swiech K; Malmegrim KCR
Stem Cell Res Ther; 2019 May; 10(1):131. PubMed ID: 31046833
[TBL] [Abstract][Full Text] [Related]
2. Use of priming strategies to advance the clinical application of mesenchymal stromal/stem cell-based therapy.
Miceli V
World J Stem Cells; 2024 Jan; 16(1):7-18. PubMed ID: 38292438
[TBL] [Abstract][Full Text] [Related]
3. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors.
Saldaña L; Bensiamar F; Vallés G; Mancebo FJ; García-Rey E; Vilaboa N
Stem Cell Res Ther; 2019 Feb; 10(1):58. PubMed ID: 30760316
[TBL] [Abstract][Full Text] [Related]
4. Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use.
Amati E; Sella S; Perbellini O; Alghisi A; Bernardi M; Chieregato K; Lievore C; Peserico D; Rigno M; Zilio A; Ruggeri M; Rodeghiero F; Astori G
Stem Cell Res Ther; 2017 Jan; 8(1):14. PubMed ID: 28115021
[TBL] [Abstract][Full Text] [Related]
5. Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion.
Srinivasan A; Sathiyanathan P; Yin L; Liu TM; Lam A; Ravikumar M; Smith RAA; Loh HP; Zhang Y; Ling L; Ng SK; Yang YS; Lezhava A; Hui J; Oh S; Cool SM
Cytotherapy; 2022 May; 24(5):456-472. PubMed ID: 35227601
[TBL] [Abstract][Full Text] [Related]
6. Increased Mesenchymal Stem Cell Functionalization in Three-Dimensional Manufacturing Settings for Enhanced Therapeutic Applications.
Kouroupis D; Correa D
Front Bioeng Biotechnol; 2021; 9():621748. PubMed ID: 33644016
[TBL] [Abstract][Full Text] [Related]
7. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.
Barrachina L; Remacha AR; Romero A; Vázquez FJ; Albareda J; Prades M; Gosálvez J; Roy R; Zaragoza P; Martín-Burriel I; Rodellar C
Stem Cells Dev; 2017 Jan; 26(1):15-24. PubMed ID: 27712399
[TBL] [Abstract][Full Text] [Related]
8. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells.
Sarsenova M; Kim Y; Raziyeva K; Kazybay B; Ogay V; Saparov A
Front Immunol; 2022; 13():1010399. PubMed ID: 36211399
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic potential of human mesenchymal stromal cells secreted components: a problem with standartization].
Sagaradze GD; Grigorieva OA; Efimenko AY; Chaplenko AA; Suslina SN; Sysoeva VY; Kalinina NI; Akopyan ZhA; Tkachuk VA
Biomed Khim; 2015; 61(6):750-9. PubMed ID: 26716748
[TBL] [Abstract][Full Text] [Related]
10. Failure to launch commercially-approved mesenchymal stromal cell therapies: what's the path forward? Proceedings of the International Society for Cell & Gene Therapy (ISCT) Annual Meeting Roundtable held in May 2023, Palais des Congrès de Paris, Organized by the ISCT MSC Scientific Committee.
Robb KP; Galipeau J; Shi Y; Schuster M; Martin I; Viswanathan S
Cytotherapy; 2024 May; 26(5):413-417. PubMed ID: 37804284
[TBL] [Abstract][Full Text] [Related]
11. Organ-specific migration of mesenchymal stromal cells: Who, when, where and why?
Cornelissen AS; Maijenburg MW; Nolte MA; Voermans C
Immunol Lett; 2015 Dec; 168(2):159-69. PubMed ID: 26187508
[TBL] [Abstract][Full Text] [Related]
12. Priming strategies for controlling stem cell fate: Applications and challenges in dental tissue regeneration.
Zhang SY; Ren JY; Yang B
World J Stem Cells; 2021 Nov; 13(11):1625-1646. PubMed ID: 34909115
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cell migration: possibilities to improve cellular therapy.
Maijenburg MW; van der Schoot CE; Voermans C
Stem Cells Dev; 2012 Jan; 21(1):19-29. PubMed ID: 21732817
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 Indicates Therapeutic Efficacy of Mesenchymal Stem Cells in Experimental Traumatic Brain Injury.
Kota DJ; Prabhakara KS; Toledano-Furman N; Bhattarai D; Chen Q; DiCarlo B; Smith P; Triolo F; Wenzel PL; Cox CS; Olson SD
Stem Cells; 2017 May; 35(5):1416-1430. PubMed ID: 28233425
[TBL] [Abstract][Full Text] [Related]
15. Persistent tailoring of MSC activation through genetic priming.
Beauregard MA; Bedford GC; Brenner DA; Sanchez Solis LD; Nishiguchi T; Abhimanyu ; Longlax SC; Mahata B; Veiseh O; Wenzel PL; DiNardo AR; Hilton IB; Diehl MR
bioRxiv; 2024 Feb; ():. PubMed ID: 38370626
[TBL] [Abstract][Full Text] [Related]
16. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.
Barrachina L; Remacha AR; Romero A; Vázquez FJ; Albareda J; Prades M; Ranera B; Zaragoza P; Martín-Burriel I; Rodellar C
Vet Immunol Immunopathol; 2016 Mar; 171():57-65. PubMed ID: 26964718
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cell therapy to promote cardiac tissue regeneration and repair.
Bartczak A; McGilvray I; Keating A
Curr Opin Organ Transplant; 2017 Feb; 22(1):86-96. PubMed ID: 28005573
[TBL] [Abstract][Full Text] [Related]
18. The immunomodulatory function of equine MSCs is enhanced by priming through an inflammatory microenvironment or TLR3 ligand.
Cassano JM; Schnabel LV; Goodale MB; Fortier LA
Vet Immunol Immunopathol; 2018 Jan; 195():33-39. PubMed ID: 29249315
[TBL] [Abstract][Full Text] [Related]
19. High Aldehyde Dehydrogenase Activity Identifies a Subset of Human Mesenchymal Stromal Cells with Vascular Regenerative Potential.
Sherman SE; Kuljanin M; Cooper TT; Putman DM; Lajoie GA; Hess DA
Stem Cells; 2017 Jun; 35(6):1542-1553. PubMed ID: 28295901
[TBL] [Abstract][Full Text] [Related]
20. Conditioned Medium from Human Mesenchymal Stromal Cells: Towards the Clinical Translation.
Sagaradze G; Grigorieva O; Nimiritsky P; Basalova N; Kalinina N; Akopyan Z; Efimenko A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
